SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has turned the discussion from Black Monday crash warnings to whether the market can sustain the bounce. Traders debate whether it reflects genuine dip-buying or a fragile overnight short-covering move, with some linking optimism to possible Russia-Ukraine developments and easing oil prices while others expect a reversal.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for SELLASs REGAL Phase 3 trial to reach its 80th death eventand the subsequent final analysisdominates discussion; the last disclosed count was 78, and the company has not confirmed the trigger. Bulls interpret the delay and quiet period as a possible sign of longer survival and speculate about an ASH data reveal, while skeptics see uncertainty around the trial and disclosure timeline; the stocks sharp decline has intensified that debate.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has put QQQ under pressure, while a strong rebound in futures prompted traders to debate whether the bounce can hold or is a bull trap. Black Monday anniversary crash warnings amplified the volatility, but many traders dismissed them as the rebound gathered momentum.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid IPO lockup expirations that make additional insider and employee shares eligible for sale, compounded by a broader AI and semiconductor selloff. Traders disagree on whether the added supply and concerns about valuation, scalability, and customer concentration will prolong the decline or whether the selloff is overdone given Cerebras inference technology.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as investors question the sectors debt-fueled expansion, financing costs, and path to returns. Traders are split between viewing the decline as an overdone pullbackoften arguing Nebius is better positioned than some peersand expecting further downside amid sector-wide risk concerns.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO updates on Iovances lifileucel program are driving attention, especially mature frontline melanoma data for lifileucel plus pembrolizumab that traders view as showing durable activity. The reaction is mixed: some see the results as supportive of the ongoing Phase 3 trial, while others argue the small cohort and largely consistent readout limit how much is new; early sarcoma results are also being watched cautiously pending larger-trial validation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, with its 3 leverage magnifying losses and the subsequent rebound. Traders are split between buying an oversold bounce and expecting more downside amid concerns about AI spending and debt, Chinese competition, and persistent inflation.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A strong quarterly report and upbeat cloud outlook drove a sharp rally, with traders also discussing Atlassians AI products as evidence that enterprise software can benefit from rather than be displaced by AI. Some see cloud demand and improving execution supporting the recovery, while others warn the run-up is overextended and point to valuation and AI-related seat-compression risks.

Roundhill ETF Trust - Roundhill Memory ETF

DRAM is drawing attention amid a sharp selloff in memory stocks, with traders citing fears that Chinas CXMT advances could add supply and pressure pricing, alongside doubts about AI data-center demand and financing. The debate pits those bearish concerns against dip-buyers who argue AI-driven memory demand remains durable; no single cause is confirmed as the sole driver.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas push into stablecoin payments is drawing attention alongside its move to fresh highs, with traders also citing momentum and China-market access as positives. The reaction is broadly bullish, though some warn the stock looks overextended or expensive.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Reports Lower Clinical Event Risk With Acoramidis Vs Tafamidis In Heart Amyloidosis

(RTTNews) - BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM...

BridgeBio Pharma Becomes Oversold (BBIO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis DayPR NewswirePALO ALTO, Calif., Oct. 6, 2026October 6 YouTube premiere featuring Sway...

Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence

ExxonMobil, ADP and Cadence highlight today's analyst reports, with growth drivers, market risks and strategic moves shaping their outlooks.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$66.39
Prev Close	$67.13
Open	$67.03
Dividend Yield	0.00%
50-Day Moving Average	$72.94
Beta	1.20
Avg. Volume	2.78M
PE Ratio	-18.60

52-Week High	$93.42
52-Week Low	$52.75
Market Capitalization	$12.98B
EPS (Annual)	-$3.79
Price to Book	-5.15
Revenue Per Employee	$598,421.93

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBIO Fundamentals